DrugPatentWatch Database Preview
SANCUSO Drug Profile
see a sample report or, see our see our flat-rate plans
When do Sancuso patents expire, and what generic alternatives are available?
This drug has forty patent family members in thirty-one countries.
The generic ingredient in SANCUSO is granisetron. There are twenty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the granisetron profile page.
Summary for SANCUSO
| International Patents: | 40 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 34 |
| Clinical Trials: | 15 |
| Patent Applications: | 4,073 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SANCUSO |
| DailyMed Link: | SANCUSO at DailyMed |
Generic Entry Opportunity Date for SANCUSO
Generic Entry Date for SANCUSO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
FILM, EXTENDED RELEASE;TRANSDERMAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for SANCUSO
| Drug Class | Serotonin-3 Receptor Antagonist |
| Mechanism of Action | Serotonin 3 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for SANCUSO
Synonyms for SANCUSO
| 1-Methyl-1H-indazole-3-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide |
| 1-METHYL-N-((1R,3R,5S)-9-METHYL-9-AZABICYCLO[3.3.1]NONAN-3-YL)-1H-INDAZOLE-3-CARBOXAMIDE |
| 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-indazole-3-carboxamide |
| 1-Methyl-N-(9-methyl-endo-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide |
| 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide |
| 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide |
| 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-7-yl]indazole-3-carboxamide |
| 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide |
| 107007-99-8 (mono-hydrochloride) |
| 109889-09-0 |
| 121061-98-1 |
| 124998-65-8 |
| 1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo- |
| 1H-INDAZOLE-3-CARBOXAMIDE, 1-METHYL-N-[(3-ENDO)-9-METHYL-9-AZABICYCLO[3.3.1]NON-3-YL]- |
| 3702AH |
| 889g090 |
| A802101 |
| AB00918713-07 |
| AB07494 |
| AC-8910 |
| AC1NR4P1 |
| AKOS025402424 |
| AN-7538 |
| APF 530 |
| APF530 |
| API0005490 |
| BDBM50443668 |
| BDBM50449636 |
| BIDD:GT0272 |
| BRL 43694 |
| BRL 43964 |
| BRL-43694 |
| C07023 |
| CCG-221158 |
| CHEBI:5537 |
| CHEBI:94501 |
| CHEMBL1290003 |
| D04370 |
| D0J5KF |
| DB00889 |
| DL-166 |
| DTXSID0023111 |
| ENDO-GRANISETRON |
| FT-0626805 |
| GRANESETRON |
| granisetron |
| Granisetron (JAN/USAN/INN) |
| Granisetron (USAN/INN) |
| Granisetron [USAN:INN:BAN:JAN] |
| Granisetron Monohydrochloride |
| Granisetronum |
| GTPL2300 |
| HMS2089P14 |
| Kevatril |
| Kevatril|||1-Methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide, |
| Kytril (TN) |
| Q-101870 |
| Sancuso (TN) |
| SCHEMBL34178 |
| SCHEMBL4890 |
| SCHEMBL4891 |
| Sustol |
| UNII-WZG3J2MCOL |
| VA11035 |
| W-5139 |
| WZG3J2MCOL |
| ZINC100018852 |
| ZINC100018854 |
| ZINC347 |
US Patents and Regulatory Information for SANCUSO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin | SANCUSO | granisetron | FILM, EXTENDED RELEASE;TRANSDERMAL | 022198-001 | Sep 12, 2008 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for SANCUSO
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Transdermal System | 3.1 mg/24 hrs | ➤ Subscribe | ➤ Try a Free Trial |
see a sample report or, see our see our flat-rate plans
International Patents for SANCUSO
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Germany | 602004007888 | ➤ Try a Free Trial |
| China | 102416009 | ➤ Try a Free Trial |
| Austria | 368454 | ➤ Try a Free Trial |
| Georgia, Republic of | P20084390 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
